Literature DB >> 18721530

Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes.

Karsten Müssig, Arzu Oncü, Philipp Lindauer, Alexandra Heininger, Hermann Aebert, Klaus Unertl, Gerhard Ziemer, Hans-Ulrich Häring, Jens J Holst, Baptist Gallwitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18721530     DOI： 10.1016/j.amjcard.2008.06.029

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  33 in total

Review 1.  Cardiovascular effects of incretin-based therapies.

Authors:  Michael Lehrke; Nikolaus Marx
Journal:  Rev Diabet Stud       Date:  2011-11-10

2.  [Cardiovascular effects of incretin-based therapies].

Authors:  M Lehrke; N Marx
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

Review 3.  Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.

Authors:  Stacey A Seggelke; Mark C Lindsay; Ingrid Hazlett; Rebecca Sanagorski; Robert H Eckel; Cecilia C Low Wang
Journal:  Curr Diab Rep       Date:  2017-08       Impact factor: 4.810

Review 4.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

Review 5.  The cardiovascular effects of GLP-1 receptor agonists.

Authors:  Theodore Okerson; Robert J Chilton
Journal:  Cardiovasc Ther       Date:  2010-12-19       Impact factor: 3.023

Review 6.  Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.

Authors:  Baptist Gallwitz
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

7.  Incretins in the ICU: is insulin on its way out?

Authors:  Michelle A Kovalaske; Gunjan Y Gandhi
Journal:  Crit Care       Date:  2009-07-02       Impact factor: 9.097

Review 8.  The evolving place of incretin-based therapies in type 2 diabetes.

Authors:  Baptist Gallwitz
Journal:  Pediatr Nephrol       Date:  2010-02-04       Impact factor: 3.714

9.  The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.

Authors:  Adam M Deane; Marianne J Chapman; Robert J L Fraser; Carly M Burgstad; Laura K Besanko; Michael Horowitz
Journal:  Crit Care       Date:  2009-05-13       Impact factor: 9.097

10.  Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

Authors:  Joan Khoo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.